Stephanie C Petterson1, Kevin D Plancher2. 1. Orthopaedic Foundation, 2777 Summer Street, Suite 500, Stamford, CT, 06905, USA. 2. Albert Einstein College of Medicine/Montefiore Hospital, Plancher Orthopaedics and Sports Medicine, 1160 Park Avenue, New York, NY, 10128, USA. kplancher@plancherortho.com.
Abstract
PURPOSE: The primary objective was to demonstrate the safety and effectiveness of Monovisc™ in the relief of joint pain in patients with idiopathic knee OA compared to saline injection. It was hypothesized that patient success, defined as ≥ 50% improvement from baseline and ≥ 20 mm absolute improvement from baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) visual analog scale (VAS) pain score, would be greater in the Monovisc™ group compared to the Saline control group. METHODS: In this multicenter, double-blind, randomized, placebo-controlled trial, patients with idiopathic, symptomatic, knee OA were randomized to either 4 ml single injection of Monovisc™ or 4 ml injection of 0.9% saline. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used to assess patient outcomes at 2, 4, 8, 12, 20, and 26 weeks post-injection. The primary effectiveness endpoint was a 50% improvement and ≥ 20 mm improvement from baseline in the WOMAC pain through 26 weeks. Secondary outcome measures included a ≥ 20 mm improvement from baseline on the WOMAC physical function, patient global assessment, evaluator global assessment, and knee range of motion. RESULTS:369 patients (154 male, 215 female) were randomized to either Monovisc™ or saline. The Monovisc™ group had a significantly greater rate of patient success (e.g. ≥ 50% improvement and ≥ 20 mm absolute improvement from baseline in the WOMAC pain through Week 26) compared to saline (p = 0.043). CONCLUSIONS: Monovisc™, a single-injection intra-articular HA device, is a safe and effective treatment for providing a clinically meaningful reduction in knee pain within 2 weeks. The results of this study support the use of a single injection of hyaluronic acid (Monovisc™) for patients with symptomatic knee OA in patients older than 45 years, as a safe and effective alternative for patients who may want an alternative treatment modality or may not be candidates for partial or total knee replacement. LEVEL OF EVIDENCE: I, multicenter, double-blind, randomized, placebo-controlled trial.
RCT Entities:
PURPOSE: The primary objective was to demonstrate the safety and effectiveness of Monovisc™ in the relief of joint pain in patients with idiopathic knee OA compared to saline injection. It was hypothesized that patient success, defined as ≥ 50% improvement from baseline and ≥ 20 mm absolute improvement from baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) visual analog scale (VAS) pain score, would be greater in the Monovisc™ group compared to the Saline control group. METHODS: In this multicenter, double-blind, randomized, placebo-controlled trial, patients with idiopathic, symptomatic, knee OA were randomized to either 4 ml single injection of Monovisc™ or 4 ml injection of 0.9% saline. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used to assess patient outcomes at 2, 4, 8, 12, 20, and 26 weeks post-injection. The primary effectiveness endpoint was a 50% improvement and ≥ 20 mm improvement from baseline in the WOMAC pain through 26 weeks. Secondary outcome measures included a ≥ 20 mm improvement from baseline on the WOMAC physical function, patient global assessment, evaluator global assessment, and knee range of motion. RESULTS: 369 patients (154 male, 215 female) were randomized to either Monovisc™ or saline. The Monovisc™ group had a significantly greater rate of patient success (e.g. ≥ 50% improvement and ≥ 20 mm absolute improvement from baseline in the WOMAC pain through Week 26) compared to saline (p = 0.043). CONCLUSIONS: Monovisc™, a single-injection intra-articular HA device, is a safe and effective treatment for providing a clinically meaningful reduction in knee pain within 2 weeks. The results of this study support the use of a single injection of hyaluronic acid (Monovisc™) for patients with symptomatic knee OA in patients older than 45 years, as a safe and effective alternative for patients who may want an alternative treatment modality or may not be candidates for partial or total knee replacement. LEVEL OF EVIDENCE: I, multicenter, double-blind, randomized, placebo-controlled trial.
Authors: Jacquelin Peck; Annabel Slovek; Paulo Miro; Neeraj Vij; Blake Traube; Christopher Lee; Amnon A Berger; Hisham Kassem; Alan D Kaye; William F Sherman; Alaa Abd-Elsayed Journal: Orthop Rev (Pavia) Date: 2021-07-10
Authors: Samantha Knott; Dylan Curry; Neil Zhao; Pallavi Metgud; Sana S Dastgheyb; Caroline Purtill; Marc Harwood; Antonia F Chen; Thomas P Schaer; Michael Otto; Noreen J Hickok Journal: Front Microbiol Date: 2021-04-29 Impact factor: 6.064
Authors: Larry E Miller; Samir Bhattacharyya; William R Parrish; Michael Fredericson; Brad Bisson; Roy D Altman Journal: Cartilage Date: 2019-11-16 Impact factor: 3.117
Authors: Germain Honvo; Raveendhara R Bannuru; Olivier Bruyère; Francois Rannou; Gabriel Herrero-Beaumont; Daniel Uebelhart; Cyrus Cooper; Nigel Arden; Philip G Conaghan; Jean-Yves Reginster; Thierry Thomas; Tim McAlindon Journal: Drugs Aging Date: 2019-04 Impact factor: 3.923
Authors: Davide Previtali; Giulia Merli; Giorgio Di Laura Frattura; Christian Candrian; Stefano Zaffagnini; Giuseppe Filardo Journal: Cartilage Date: 2020-03-18 Impact factor: 4.634